Clinical Trial

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

Name: Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer. — clinical trial record (NCT06888674)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This study is a single-center, open-label clinical study to evaluate the feasibility and safety of personalized tumor neoantigen mRNA therapy (iNeo-Vac-R01) in combination with PD-1 antibody and standard chemotherapy regimen as adjuvant treatment for postoperative resectable pancreatic cancer.

Trial Details

NCT Number	NCT06888674
Lead Sponsor	Zhejiang University Collaborators: Hangzhou Neoantigen Therapeutics Co., Ltd.
Conditions	Pancreatic Cancer Resectable
Enrollment	60 participants
Start Date	2025-04-01
Primary Completion	2027-04-01 (estimated)
Study Completion	2029-04-01 (estimated)
Updated on ClinicalTrials.gov	2025-03-21